A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Exclusion Criteria

• •Stage 5 CKD as defined by eGFR \<15 mL/min/1.73 m\^2 OR having required dialysis
• •Rapidly progressing renal dysfunction likely to require renal replacement
• •History of a transplanted organ
• •Type 1 diabetes mellitus
• •At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥90 mmHg with or without antihypertensive medication
• •An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycemia in the past 3 months prior to the Screening Visit
• •Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke)
• •Acute or chronic hepatitis
• •Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis
• •Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit
• •Self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma
• •Known history of untreated proliferative retinopathy